deltatrials
Unknown PHASE1 INTERVENTIONAL 1-arm NCT02456350

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Genetically Engineered T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor for Treatment of Patients With B Cell Malignancies

Sponsor: Shenzhen Institute for Innovation and Translational Medicine

Conditions Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Lymphoma
Interventions Anti-CD19-CAR transduced T cells Cyclophosphamide Fludarabine
Updated 7 times since 2017 Last updated: Aug 1, 2016 Started: Apr 30, 2015 Primary completion: Dec 31, 2019 Completion: Dec 31, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia, this trial is ongoing. The trial is conducted by Shenzhen Institute for Innovation and Translational Medicine and has accumulated 7 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~May 2017 · 4 months · monthly snapshotRecruiting~May 2017 – ~Jun 2018 · 13 months · monthly snapshotRecruiting~Jun 2018 – ~Jan 2020 · 19 months · monthly snapshotRecruiting~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1

  4. Jan 2020 — Jan 2021 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

  5. Jun 2018 — Jan 2020 [monthly]

    Recruiting PHASE1

▶ Show 2 earlier versions

  1. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  2. Jan 2017 — May 2017 [monthly]

    Recruiting PHASE1

    First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shenzhen Institute for Innovation and Translational Medicine
  • Shenzhen Second People's Hospital
Data source: Shenzhen Second People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations